Claude Geoffrey Davis

This inventor holds 9 USPTO granted patents and 8 published patent applications, plus 1 CIPO patent and 8 EPO patents. Top assignees: Angelica Therapeutics, Inc., Chimeros, Inc., Other. Active years: 1993-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Claude Geoffrey Davis. Retrieved from https://idiyas.com/inventor/claude-geoffrey-davis

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 9 (Patent Applications = 8)

% Patents Active = 88.9

CIPO Patents = 1 (Patent Applications = 4)

EPO Patents = 8 (Patent Applications = 8)

Average Co-Inventor Count = 2.3

ph-index = 4

Forward Citations = 154(Granted Patents)

Location History:

San Francisco, CA (US) (1993)
Melbourne, FL (US) (2000)
San Mateo, CA (US) (2011 - 2013)
Elizabeth, NJ (US) (2018)
Auburn, CA (US) (2018 - 2021)

Company Filing History:

3 out of 3

Angelica Therapeutics, Inc.

5 out of 834,453

Other

patents

Years Active: 1993-2021

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10961509 - Engineered endothelial cells expressing an ETS transcription factor (2021-03-30),

2. 10947500 - Neural cells expressing adenovirus E4ORF1, and methods of making and using the same (2021-03-16),

3. 10059750 - Modified toxins (2018-08-28),

4. 9976698 - Multi-angle television wall mount (2018-05-22),

5. 8470314 - Modified toxins (2013-06-25),

6. 8252897 - Modified toxins (2012-08-28),

7. 8067011 - Compositions and methods for treating B-cell malignancies (2011-11-29),

8. 6029600 - Clean hands assured (2000-02-29),

9. 5258289 - Method for the selecting of genes encoding catalytic antibodies (1993-11-02),

Title: Claude Geoffrey Davis: Innovator in Engineered Cells

Introduction

Claude Geoffrey Davis is a notable inventor based in Auburn, CA (US), recognized for his contributions to the field of engineered cells. With a total of 9 patents, Davis has made significant strides in biotechnology, particularly in the development of specialized cells for medical applications.

Latest Patents

Davis's latest patents include innovative work on engineered endothelial cells expressing an ETS transcription factor. This invention relates to methods of creating and utilizing engineered endothelial cells, such as E40RF1+ ETV2+ cells, for co-culture applications. Another significant patent involves neural cells expressing adenovirus E4ORF1, which provides engineered neural cells, neural stem cells, or neural progenitor cells containing a nucleotide sequence that encodes an adenovirus E40RF1 polypeptide. This invention also outlines methods for making and using these engineered cells.

Career Highlights

Throughout his career, Davis has worked with various companies, including Angelica Therapeutics, Inc. His work has focused on advancing the understanding and application of engineered cells in therapeutic settings.

Collaborations

Davis has collaborated with notable individuals in his field, including Deepshikha Datta and Matthew Paul Baker. These collaborations have contributed to the development of his innovative patents and research.

Conclusion

Claude Geoffrey Davis stands out as a prominent inventor in the realm of engineered cells, with a strong portfolio of patents that reflect his dedication to advancing biotechnology. His work continues to influence the field and pave the way for future innovations.

Profile summary based on public USPTO records.